In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

Romania's Sibiu County Emergency Clinical Hospital will receive a robotic system to prepare cytostatic drugs needed by cancer ...

In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have ...